Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of Sulfasalazine for the treatment of progressing malignant gliomas in adults

BACKGROUND: Sulfasalazine, a NF-kappaB and x(c)-cystine/glutamate antiport inhibitor, has demonstrated a strong antitumoral potential in preclinical models of malignant gliomas. As it presents an excellent safety profile, we initiated a phase 1/2 clinical study of this anti-inflammatory drug for the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Robe, Pierre A, Martin, Didier H, Nguyen-Khac, Minh T, Artesi, Maria, Deprez, Manuel, Albert, Adelin, Vanbelle, Sophie, Califice, Stephane, Bredel, Markus, Bours, Vincent
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2009
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2771045/
https://ncbi.nlm.nih.gov/pubmed/19840379
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-9-372
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados